Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats.

Sebbag L, Allbaugh RA, Wehrman RF, Uhl LK, Ben-Shlomo G, Chen T, Mochel JP.

J Ocul Pharmacol Ther. 2019 Aug 8. doi: 10.1089/jop.2019.0038. [Epub ahead of print]

PMID:
31381493
2.

Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative.

Upadhyay VA, Geisler BP, Sun L, Uhl L, Kaufman RM, Stowell C, Makar RS, Bendapudi PK.

Br J Haematol. 2019 Aug;186(3):490-498. doi: 10.1111/bjh.15932. Epub 2019 May 26.

PMID:
31131442
3.

Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.

Sun L, Mack J, Li A, Ryu J, Upadhyay VA, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Makar RS, Bendapudi PK.

Blood Adv. 2019 May 14;3(9):1512-1518. doi: 10.1182/bloodadvances.2019031039.

4.

Clinical features of cats with aqueous tear deficiency: a retrospective case series of 10 patients (17 eyes).

Uhl LK, Saito A, Iwashita H, Maggs DJ, Mochel JP, Sebbag L.

J Feline Med Surg. 2019 Oct;21(10):944-950. doi: 10.1177/1098612X18810867. Epub 2018 Nov 12.

PMID:
30417738
5.

Paracrine costimulation of IFN-γ signaling by integrins modulates CD8 T cell differentiation.

Krummel MF, Mahale JN, Uhl LFK, Hardison EA, Mujal AM, Mazet JM, Weber RJ, Gartner ZJ, Gérard A.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11585-11590. doi: 10.1073/pnas.1804556115. Epub 2018 Oct 22.

6.

To transfuse or not transfuse: an intensive appraisal of red blood cell transfusions in the ICU.

Hayes MM, Uhl L.

Curr Opin Hematol. 2018 Nov;25(6):468-472. doi: 10.1097/MOH.0000000000000460. Review.

PMID:
30281035
7.

Management of a Hospital Transfusion Service During a Nationwide Blood Product Shortage.

O'Brien KL, Mohammed M, Uhl L.

Arch Pathol Lab Med. 2018 Jul;142(7):779-781. doi: 10.5858/arpa.2017-0483-LE. No abstract available.

PMID:
29939778
8.

Red cell genotyping precision medicine: a conference summary.

Denomme GA, Anani WQ, Avent ND, Bein G, Briggs LB, Lapadat RC, Montemayor C, Rios M, St-Louis M, Uhl L, Wendel S, Flegel WA.

Ther Adv Hematol. 2017 Oct;8(10):277-291. doi: 10.1177/2040620717729128. Epub 2017 Sep 13. Review.

9.

A passive physical model for DnaK chaperoning.

Uhl L, Dumont A, Dukan S.

Phys Biol. 2018 Jan 11;15(2):026003. doi: 10.1088/1478-3975/aa9130.

PMID:
28980528
10.

Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial.

Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ.

Blood. 2017 Sep 7;130(10):1247-1258. doi: 10.1182/blood-2017-01-757930. Epub 2017 Jul 5.

11.

Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial.

Uhl L, Kiss JE, Malynn E, Terrell DR, Vesely SK, George JN.

Transfusion. 2017 Oct;57(10):2532-2538. doi: 10.1111/trf.14193. Epub 2017 Jul 3. No abstract available.

PMID:
28671324
12.

Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency.

Li A, Bendapudi PK, Uhl L, Hamdan A, Kaufman RM, Makar RS.

Transfusion. 2017 Sep;57(9):2151-2158. doi: 10.1111/trf.14181. Epub 2017 Jun 20.

PMID:
28635017
13.

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R, Azzopardi SA, Uhl LFK, Saeed M, Sevilla-Reyes EE, Agudelo M, Yao KH, Golijanin J, Gristick HB, Lee YE, Hurley A, Caskey M, Pai J, Oliveira T, Wunder EA Jr, Sacramento G, Nery N Jr, Orge C, Costa F, Reis MG, Thomas NM, Eisenreich T, Weinberger DM, de Almeida ARP, West AP Jr, Rice CM, Bjorkman PJ, Reyes-Teran G, Ko AI, MacDonald MR, Nussenzweig MC.

Cell. 2017 May 4;169(4):597-609.e11. doi: 10.1016/j.cell.2017.04.024.

14.

Conservation of the group O, Rhesus D negative blood supply.

Uhl L.

Lancet Haematol. 2017 May;4(5):e195-e196. doi: 10.1016/S2352-3026(17)30057-1. No abstract available.

PMID:
28460813
15.

Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.

Kuter DJ, Konkle BA, Hamza TH, Uhl L, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais BS, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland JG, Neufeld E, Bussel JB, Ortel TL.

Am J Hematol. 2017 Aug;92(8):730-738. doi: 10.1002/ajh.24759. Epub 2017 Apr 26.

16.

Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.

Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS.

Lancet Haematol. 2017 Apr;4(4):e157-e164. doi: 10.1016/S2352-3026(17)30026-1. Epub 2017 Mar 2.

PMID:
28259520
17.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.

18.

Hemovigilance in Massachusetts and the adoption of statewide hospital blood bank reporting using the National Healthcare Safety Network.

Cumming M, Osinski A, O'Hearn L, Waksmonski P, Herman M, Gordon D, Griffiths E, Knox K, McHale E, Quillen K, Rios J, Pisciotto P, Uhl L, DeMaria A Jr, Andrzejewski C Jr.

Transfusion. 2017 Feb;57(2):478-483. doi: 10.1111/trf.13872. Epub 2016 Oct 23.

PMID:
27774608
19.

Hydrogen Peroxide Induced Cell Death: The Major Defences Relative Roles and Consequences in E. coli.

Uhl L, Dukan S.

PLoS One. 2016 Aug 5;11(8):e0159706. doi: 10.1371/journal.pone.0159706. eCollection 2016.

20.

How do we manage blood product support in the massively hemorrhaging obstetric patient?

O'Brien KL, Uhl L.

Transfusion. 2016 Sep;56(9):2165-71. doi: 10.1111/trf.13753. Epub 2016 Aug 4.

PMID:
27488384
21.

Hydrogen peroxide induced cell death: One or two modes of action?

Uhl L, Gerstel A, Chabalier M, Dukan S.

Heliyon. 2015 Dec 23;1(4):e00049. doi: 10.1016/j.heliyon.2015.e00049. eCollection 2015 Dec.

22.

Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study.

Li A, Makar RS, Hurwitz S, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Bendapudi PK.

Transfusion. 2016 Aug;56(8):2069-77. doi: 10.1111/trf.13654. Epub 2016 May 27.

PMID:
27232383
23.

Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.

Bendapudi PK, Li A, Hamdan A, Uhl L, Kaufman R, Stowell C, Dzik W, Makar RS.

Br J Haematol. 2015 Dec;171(5):836-44. doi: 10.1111/bjh.13658. Epub 2015 Aug 28.

PMID:
26314936
24.

Effects of red-cell storage duration on patients undergoing cardiac surgery.

Steiner ME, Ness PM, Assmann SF, Triulzi DJ, Sloan SR, Delaney M, Granger S, Bennett-Guerrero E, Blajchman MA, Scavo V, Carson JL, Levy JH, Whitman G, D'Andrea P, Pulkrabek S, Ortel TL, Bornikova L, Raife T, Puca KE, Kaufman RM, Nuttall GA, Young PP, Youssef S, Engelman R, Greilich PE, Miles R, Josephson CD, Bracey A, Cooke R, McCullough J, Hunsaker R, Uhl L, McFarland JG, Park Y, Cushing MM, Klodell CT, Karanam R, Roberts PR, Dyke C, Hod EA, Stowell CP.

N Engl J Med. 2015 Apr 9;372(15):1419-29. doi: 10.1056/NEJMoa1414219.

25.

A case for stocking O D+ red blood cells in emergency room trauma bays.

Meyer E, Uhl L.

Transfusion. 2015 Apr;55(4):791-5. doi: 10.1111/trf.12925. Epub 2014 Dec 1.

PMID:
25444310
26.

Provision of KEL1-negative blood to obstetric patients: a 3-year single-institution retrospective review.

O'Brien KL, Kim YA, Haspel RL, Uhl L.

Transfusion. 2015 Mar;55(3):599-604; quiz 598. doi: 10.1111/trf.12814. Epub 2014 Aug 13. Review.

PMID:
25118004
27.

Anti-D alloimmunization after D-incompatible platelet transfusions: a 14-year single-institution retrospective review.

O'Brien KL, Haspel RL, Uhl L.

Transfusion. 2014 Mar;54(3):650-4. doi: 10.1111/trf.12341. Epub 2013 Jul 7.

PMID:
23829356
28.

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D.

Clin Cancer Res. 2013 Jul 1;19(13):3640-8. doi: 10.1158/1078-0432.CCR-13-0282. Epub 2013 May 17.

29.

Telltale signs of progress in the management of thrombotic thrombocytopenic purpura.

Kiss JE, Uhl L.

Transfusion. 2012 Dec;52(12):2498-501. doi: 10.1111/j.1537-2995.2012.03946.x. No abstract available.

PMID:
23231672
30.

Patient blood management: a 68-year-old woman contemplating autologous blood donation before elective surgery.

Uhl L.

JAMA. 2011 Nov 2;306(17):1902-10. doi: 10.1001/jama.2011.1526. Epub 2011 Oct 11.

PMID:
21990097
31.

How do I audit hospital blood product utilization?

Haspel RL, Uhl L.

Transfusion. 2012 Feb;52(2):227-30. doi: 10.1111/j.1537-2995.2011.03191.x. Epub 2011 Jun 7. No abstract available.

PMID:
21649663
32.

Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.

Younk LM, Uhl L, Davis SN.

Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):753-63. doi: 10.1517/17425255.2011.579561. Epub 2011 Apr 27. Review.

PMID:
21521130
33.

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.

Blood. 2011 Jan 13;117(2):393-402. doi: 10.1182/blood-2010-04-277137. Epub 2010 Oct 28.

34.

Risk of hemolytic transfusion reactions following emergency-release RBC transfusion.

Goodell PP, Uhl L, Mohammed M, Powers AA.

Am J Clin Pathol. 2010 Aug;134(2):202-6. doi: 10.1309/AJCP9OFJN7FLTXDB.

PMID:
20660321
35.

Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population.

Wahl PM, Terrell DR, George JN, Rodgers JK, Uhl L, Cataland S, Bohn RL.

Thromb Haemost. 2010 Jun;103(6):1203-9. doi: 10.1160/TH09-08-0595. Epub 2010 Mar 29.

PMID:
20352159
36.

Commentary.

Uhl L.

Clin Chem. 2010 Mar;56(3):355-6. doi: 10.1373/clinchem.2009.140111. No abstract available.

37.

Dose of prophylactic platelet transfusions and prevention of hemorrhage.

Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S.

N Engl J Med. 2010 Feb 18;362(7):600-13. doi: 10.1056/NEJMoa0904084.

38.

Identification and evaluation of false-negative antibody screens.

Powers A, Chandrashekar S, Mohammed M, Uhl L.

Transfusion. 2010 Mar;50(3):617-21. doi: 10.1111/j.1537-2995.2009.02464.x. Epub 2009 Nov 23.

PMID:
19951323
39.

Strict adherence to a blood bank specimen labeling policy by all clinical laboratories significantly reduces the incidence of "wrong blood in tube".

O'Neill E, Richardson-Weber L, McCormack G, Uhl L, Haspel RL.

Am J Clin Pathol. 2009 Aug;132(2):164-8; quiz 306. doi: 10.1309/AJCPOJA2JRVX0IWC.

PMID:
19605809
40.

Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model.

Gaines AR, Lee-Stroka H, Byrne K, Scott DE, Uhl L, Lazarus E, Stroncek DF.

Transfusion. 2009 Jun;49(6):1050-8. doi: 10.1111/j.1537-2995.2008.02083.x. Epub 2009 Feb 9.

41.

Evaluation and management of acute hemolytic transfusion reactions.

Uhl L, Johnson ST.

Immunohematology. 2007;23(3):93-9. No abstract available.

PMID:
18284298
42.

Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.

Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA.

Exp Hematol. 2008 Apr;36(4):464-72. doi: 10.1016/j.exphem.2007.12.010. Epub 2008 Feb 8.

43.

Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia.

Chan M, Malynn E, Shaz B, Uhl L.

Am J Hematol. 2008 Mar;83(3):212-7.

44.

Apparent nonhemolytic alloantibody-induced red-cell antigen loss from transfused erythrocytes.

Powers A, Mohammed M, Uhl L, Haspel RL.

Blood. 2007 May 15;109(10):4590. No abstract available.

PMID:
17483302
45.

Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura?

Cserti CM, Landaw S, Uhl L.

J Clin Apher. 2007 Feb;22(1):21-5.

PMID:
17285617
46.

Improved strategy for mononuclear cell collection for donor lymphocyte infusions.

Shaz B, Goodarzi K, Malynn E, Uhl L.

Transfusion. 2006 Jun;46(6):1044-8.

PMID:
16734823
47.

Maximum hygiene.

Weaver A, Uhl L.

Dent Today. 2004 Nov;23(11):60, 62, 64. No abstract available.

PMID:
15622878
48.

Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.

Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA.

J Thromb Haemost. 2004 Dec;2(12):2133-7.

49.
50.

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D.

Clin Cancer Res. 2004 Jul 15;10(14):4699-708.

Supplemental Content

Support Center